Investigational Lupus Drug Blisibimod Gets Go-ahead for Phase 3 Development

The U.S. Food and Drug and the European Medicines Agency gave permission to Anthera Pharmaceuticals to submit a design for a Phase 3 trial to test the experimental drug blisibimod among patients with lupus. The FDA describes Phase 3 trial as: In Phase III trials, the experimental study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely. Learn more about the plans for the blisibimod trial at: